The Use of Immunotherapy for Treatment of Gynecologic Malignancies
Main Article Content
ABSTRACT
Gynecological malignancies continue to present significant morbidity and mortality in women notwithstanding current traditional and new targeted treatments. The advent of immunotherapy and its successes in hematologic malignancies, melanoma and lung cancer led to immense interest in exploring its effects in chemoresistant, advanced stage and recurrent gynecologic cancers. The tumor microenviroment is characteristically immunosuppressive to infiltrating cytotoxic T cells. Thus, the goal of immune based therapies is two-fold: overcome this immunosuppression and enhance tumor destruction. In this chapter, we discuss some of the preclinical studies and clinical trials investigating vaccines and other immunotherapies in gynecologic cancer patients. We present key advances in the development of cancer vaccines, adjuvants, immune modulators, adoptive cell therapies for the generation of optimal immunogenicity, and immuno persistence and the ultimate eradication of resistant, advanced, and recurrent gynecologic cancers.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.